These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 7636873)
41. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Lambert DM; DiPaolo FG; Sonveaux P; Kanyonyo M; Govaerts SJ; Hermans E; Bueb J; Delzenne NM; Tschirhart EJ Biochim Biophys Acta; 1999 Sep; 1440(2-3):266-74. PubMed ID: 10521710 [TBL] [Abstract][Full Text] [Related]
42. Cellular localization of cannabinoid receptors and activated G-proteins in rat anterior cingulate cortex. Sim-Selley LJ; Vogt LJ; Vogt BA; Childers SR Life Sci; 2002 Sep; 71(19):2217-26. PubMed ID: 12215369 [TBL] [Abstract][Full Text] [Related]
43. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. Katoch-Rouse R; Pavlova OA; Caulder T; Hoffman AF; Mukhin AG; Horti AG J Med Chem; 2003 Feb; 46(4):642-5. PubMed ID: 12570386 [TBL] [Abstract][Full Text] [Related]
44. Cannabinoid penetration into mouse brain as determined by ex vivo binding. Petitet F; Jeantaud B; Bertrand P; Imperato A Eur J Pharmacol; 1999 Jun; 374(3):417-21. PubMed ID: 10422786 [TBL] [Abstract][Full Text] [Related]
45. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Ross RA; Brockie HC; Fernando SR; Saha B; Razdan RK; Pertwee RG Br J Pharmacol; 1998 Nov; 125(6):1345-51. PubMed ID: 9863666 [TBL] [Abstract][Full Text] [Related]
46. Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments. Yousif MH; Oriowo MA Pharmacol Res; 1999 Nov; 40(5):415-21. PubMed ID: 10527656 [TBL] [Abstract][Full Text] [Related]
47. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. Breivogel CS; Sim LJ; Childers SR J Pharmacol Exp Ther; 1997 Sep; 282(3):1632-42. PubMed ID: 9316881 [TBL] [Abstract][Full Text] [Related]
48. Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity. Cano C; Goya P; Paez JA; Girón R; Sánchez E; Martín MI Bioorg Med Chem; 2007 Dec; 15(23):7480-93. PubMed ID: 17870539 [TBL] [Abstract][Full Text] [Related]
49. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977 [TBL] [Abstract][Full Text] [Related]
50. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Shim JY; Welsh WJ; Howlett AC Biopolymers; 2003; 71(2):169-89. PubMed ID: 12767117 [TBL] [Abstract][Full Text] [Related]
51. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Breivogel CS; Griffin G; Di Marzo V; Martin BR Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610 [TBL] [Abstract][Full Text] [Related]
52. Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2. Nallapaneni A; Liu J; Karanth S; Pope C Toxicology; 2006 Oct; 227(1-2):173-83. PubMed ID: 16956707 [TBL] [Abstract][Full Text] [Related]
53. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Rinaldi-Carmona M; Barth F; Héaulme M; Alonso R; Shire D; Congy C; Soubrié P; Brelière JC; Le Fur G Life Sci; 1995; 56(23-24):1941-7. PubMed ID: 7776817 [TBL] [Abstract][Full Text] [Related]
54. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells. Germain N; Boichot E; Advenier C; Berdyshev EV; Lagente V Int Immunopharmacol; 2002 Mar; 2(4):537-43. PubMed ID: 11962732 [TBL] [Abstract][Full Text] [Related]
55. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. Papahatjis DP; Nikas SP; Kourouli T; Chari R; Xu W; Pertwee RG; Makriyannis A J Med Chem; 2003 Jul; 46(15):3221-9. PubMed ID: 12852753 [TBL] [Abstract][Full Text] [Related]
56. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Song ZH; Slowey CA; Hurst DP; Reggio PH Mol Pharmacol; 1999 Oct; 56(4):834-40. PubMed ID: 10496968 [TBL] [Abstract][Full Text] [Related]
57. Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Hirst RA; Almond SL; Lambert DG Neurosci Lett; 1996 Dec; 220(2):101-4. PubMed ID: 8981483 [TBL] [Abstract][Full Text] [Related]
58. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. Ooms F; Wouters J; Oscari O; Happaerts T; Bouchard G; Carrupt PA; Testa B; Lambert DM J Med Chem; 2002 Apr; 45(9):1748-56. PubMed ID: 11960486 [TBL] [Abstract][Full Text] [Related]
59. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367 [TBL] [Abstract][Full Text] [Related]
60. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Ashton JC; Wright JL; McPartland JM; Tyndall JD Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]